Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine

The safety and efficacy of LY2963016 insulin glargine (LY IGlar) and Lantus(®) insulin glargine (IGlar), products with identical primary amino acid sequences, were assessed in subgroups of patients with type 1 (T1D, n = 452) or type 2 diabetes (T2D, n = 299) reporting prestudy IGlar treatment in 52‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Hadjiyianni, I., Dahl, D., Lacaya, L. B., Pollom, R. K., Chang, C. L., Ilag, L. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067552/
https://www.ncbi.nlm.nih.gov/pubmed/26749289
http://dx.doi.org/10.1111/dom.12628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067552/
https://www.ncbi.nlm.nih.gov/pubmed/26749289
http://dx.doi.org/10.1111/dom.12628

Ejemplares similares